Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 13/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | STAT1 | P42224 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CCR5 | P51681 | 2/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL485980 | 0.83 | F2R (0.73) | F2RMAPTSMN1; SMN2NPC1STAT1 | |
| SCHEMBL486536 | 0.81 | F2R (0.73) | F2RMEN1KMT2A | |
| SCHEMBL661530 | 0.81 | F2R (0.71) | F2RMAPTSMN1; SMN2NPC1STAT1 | |
| SCHEMBL662897 | 0.81 | F2R (0.81) | F2RMAPTSMN1; SMN2NPC1STAT1 | |
| SCHEMBL662294 | 0.80 | F2R (0.74) | F2RMAPTSMN1; SMN2NPC1STAT1 | |
| SCHEMBL663389 | 0.78 | F2R (1.00) | F2RMAPTSMN1; SMN2NPC1STAT1 | |
| SCHEMBL486133 | 0.77 | F2R (1.00) | F2RMAPTSMN1; SMN2NPC1STAT1 | |
| SCHEMBL662549 | 0.77 | F2R (0.74) | F2RMAPTSMN1; SMN2NPC1STAT1 | |
| SCHEMBL486024 | 0.77 | F2R (0.64) | F2RMAPTSMN1; SMN2NPC1STAT1 | |
| SCHEMBL10188818 | 0.76 | F2R (0.72) | F2RMAPTSMN1; SMN2NPC1STAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411363-B1 | SUBSTITUTED PIPERIDINES AS PAR-1 ANTAGONISTS | BAYER IP GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| EP-2411363-B1 | SUBSTITUTED PIPERIDINES AS PAR-1 ANTAGONISTS | BAYER IP GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-20150183773-A1 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-02 | — | — | US | disclosed |
| US-20150183773-A1 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-02 | — | — | US | disclosed |
| US-8987248-B2 | Substituted piperidines as Par-1 antagonists | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-8987248-B2 | Substituted piperidines as Par-1 antagonists | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| CN-102438985-B | Substituted piperidines as par-1 antagonists | BAYER SCHERING PHARMA AG | 2014-09-17 | — | — | CN | disclosed |
| CN-102438985-A | Substituted piperidines as par-1 antagonists | BAYER SCHERING PHARMA AG | 2012-05-02 | — | — | CN | disclosed |
| US-20120046268-A1 | Substituted piperidines as Par-1 Antagonists | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-23 | — | — | US | disclosed |
| US-20120046268-A1 | Substituted piperidines as Par-1 Antagonists | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-23 | — | — | US | disclosed |
| EP-2411363-A1 | SUBSTITUTED PIPERIDINES AS PAR-1 ANTAGONISTS | Bayer Pharma AG (DE) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010108608-A1 | SUBSTITUTED PIPERIDINES AS PAR-1 ANTAGONISTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010108608-A1 | SUBSTITUTED PIPERIDINES AS PAR-1 ANTAGONISTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183773-A1 | Substituted piperidines | VHL, PIR, PIGO | F2R 1243/4885MAPT 4722/4885SMN1; SMN2 1869/4885 |
| US-20120046268-A1 | Substituted piperidines as Par-1 Antagonists | F2R, F2RL1, F2RL3 | F2R 1/4885MAPT 4575/4885SMN1; SMN2 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.